A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
An article from
Dive Brief
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
Published Sept. 3, 2026
An illustration of a PD-L1 protein (red) on a cancer cell binding to the immune checkpoint protein PD-1 on a T cell.
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important…
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's…
Chinese biotech firm Akeso Inc has announced positive interim results from a registrational Phase-3 trial, showing that its…
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial,…
Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3…
